{{Rsnum
|rsid=12481102
|Gene=EYA2
|Chromosome=20
|position=46999130
|Orientation=plus
|GMAF=0.1088
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=EYA2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 100.0 | 0.0 | 0.0
| HCB | 54.0 | 36.5 | 9.5
| JPT | 48.7 | 46.9 | 4.4
| YRI | 96.6 | 2.0 | 1.4
| ASW | 96.4 | 3.6 | 0.0
| CHB | 54.0 | 36.5 | 9.5
| CHD | 50.5 | 45.0 | 4.6
| GIH | 94.1 | 5.9 | 0.0
| LWK | 89.1 | 10.0 | 0.9
| MEX | 65.5 | 27.6 | 6.9
| MKK | 92.3 | 7.7 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12481102
|Name_s=
|Gene_s=EYA2
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.03, combined P value= 2.84E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470227
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12481102
|overall_frequency_n=6
|overall_frequency_d=128
|overall_frequency=0.046875
|n_genomes=5
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}